A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms UNCOVER-J
- Sponsors Eli Lilly
- 25 Oct 2017 Status changed from active, no longer recruiting to completed.
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 24 Dec 2016 Results of an integrated analysis of UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J and two other phase 1 and phase 2 studies published in the Journal of the American Academy of Dermatology.